Skip to content
Search

Latest Stories

China grants Pakistan rollover on $2.4 billion loan

The move sends the Pakistan Stock Exchange’s benchmark index to a 20-month high

China grants Pakistan rollover on $2.4 billion loan

CHINA has granted Pakistan a two-year rollover on a $2.4 billion loan, Islamabad said Thursday (27), giving the debt-saddled nation breathing space in its balance-of-payments crisis.

Soaring inflation, shrinking dollar reserves and crippling foreign debt led Pakistan to the brink of default before a pivotal $3 bn IMF bailout was granted earlier this month.

Securing supplemental backing from friendly nations was a key condition for the global lender granting further support to Pakistan.

Finance minister Ishaq Dar said China's EXIM Bank had rolled over for two years principal amounts on twin debts of $1.2 bn that had been due in the fiscal years 2023/24 and 2024/25.

"Pakistan will make interest payments only,” Dar said on Twitter, recently renamed "X".

The United Arab Emirates and Saudi Arabia topped up Pakistan's forex reserves by $3 bon before the IMF standby deal was confirmed.

State forex reserves have rebounded to $8.7 bn after reaching such a low ebb that imports were heavily restricted and local industry was hobbled.

The rollover sent the Pakistan Stock Exchange's benchmark index to a 20-month high after a prolonged bearish trend.

"News of the Chinese loan rollover added to the post-IMF agreement sentiments," said Sunny Kumar, a financial analyst at Topline Securities.

"Yet full recovery of the economy is a long way ahead."

(AFP)

More For You

pharmacy

The UK spends just 9 per cent of healthcare budgets on medicines while patients face growing access gaps.

iStock

UK calls for new pharmaceutical investment to strengthen life sciences

Highlights

  • UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
  • Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
  • Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.

Investment gap

Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.

Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.

Keep ReadingShow less